Xarelto Insurance Denial Appeal Guide

Xarelto (rivaroxaban) is a direct oral anticoagulant for AFib, DVT, and PE. Insurance denials typically involve step therapy or formulary preference issues.

Why Xarelto Gets Denied

Like Eliquis, Xarelto faces step therapy and formulary preference barriers. Plans that prefer Eliquis will deny Xarelto, and vice versa. Warfarin step therapy is also common.

Common Denial Reasons

  • Warfarin step therapy required
  • Non-preferred DOAC (plan prefers Eliquis)
  • Prior authorization not obtained
  • Off-label dose or indication
  • Quantity limits

Appeal Strategy

  1. Cite once-daily dosing advantage — Xarelto is once daily vs Eliquis twice daily, improving compliance
  2. For DVT/PE treatment — Xarelto has the most indication coverage of any DOAC
  3. Document warfarin contraindications — drug interactions, INR instability, dietary concerns
  4. Specialist letter from cardiologist or hematologist
  5. Include ROCKET AF or EINSTEIN trial data as supporting evidence

Once-Daily Advantage

If medication adherence is a documented concern, the once-daily dosing of Xarelto is a medically relevant differentiator that can support your appeal over twice-daily alternatives.

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

Is Xarelto better than Eliquis?

Neither is universally better. Xarelto has once-daily dosing advantage and broader indications. Eliquis has slightly less GI bleeding in AFib trials. Your doctor should choose based on your specific clinical situation.

Can I appeal if my plan only covers warfarin?

Yes. Document why warfarin is medically inappropriate for you — INR instability, drug interactions, dietary restrictions, or fall risk all support DOAC use over warfarin.

Related Resources